Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
BASEL, Switzerland and CAMBRIDGE, Mass., Nov. 08, 2016 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced Rodger Novak, M.D., Chief Executive Officer and Founder of CRISPR Therapeutics, will present at the Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016 at the Lotte New York Palace Hotel, New York.
Event: Stifel 2016 Healthcare Conference
Date: Tuesday, November 15, 2016
Time: 11:45 AM ET
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at www.crisprtx.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform.
MEDIA CONTACTS: Jennifer Paganelli W2O Group for CRISPR 347-658-8290 [email protected] INVESTOR CONTACT: Chris Brinzey Westwicke Partners for CRISPR 339-970-2843 [email protected]
